Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: GlobeNewswire
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29 - June 2 in Chicago, Illinois. “We are pleased to share data from this important subset of r/r WM patients for whom there are no approved therapies and remaining options are restricted to salvage therapies which provide limited benefit. It is important to note that approximately 60% of drugs used for all WM patients are considered salvage therapies,” said Jarrod Longcor, chief operating officer of Cellectar. “The safety and efficacy of iopofosine observed to date are highly encouraging and underscore its potential to address a significant unmet need for patients who progress after BTK inhibitors. We believe these
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)GlobeNewswire
- Cellectar Biosciences (CLRB) was upgraded by Maxim Group from "hold" to "buy". They now have a $10.00 price target on the stock.MarketBeat
- Cellectar (CLRB) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate UpdatesGlobeNewswire
CLRB
Earnings
- 3/4/26 - Miss
CLRB
Sec Filings
- 3/4/26 - Form 8-K
- 3/4/26 - Form 10-K
- 2/13/26 - Form SCHEDULE
- CLRB's page on the SEC website